Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
Final 2025 global cohort onboarding, with applications now open for 2026WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ...
Gram-negative bacteria, notorious for their intrinsic and acquired resistance mechanisms, pose a significant threat to public health. The emergence of ...
Charles River Laboratories International Inc. has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results